Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. Transformative treatment for wet, age-related macular degeneration

Transformative treatment for wet, age-related macular degeneration

Stories Oct 23, 2023 3 minutes

A visionary approach to improved eye care could help improve patient outcomes and alleviate health care-related strain.

Age-related macular degeneration (AMD) is the leading cause of vision loss among older adults, affecting approximately 2.5 million Canadians. The condition progressively affects the macula, a part of the retina that plays a crucial role in our vision precision. With time, AMD can result in blurred vision or a blind spot in the centre of a person's field of vision.

There are two main types of AMD. Dry AMD is more common and occurs when the cells of the macula gradually break down. On the other hand, wet AMD is less common, but more severe. Wet AMD is caused by abnormal blood vessel growth in the macula that results in the accumulation of fluid or blood. If left untreated, wet AMD can result in irreversible vision loss.

Currently, patients with wet AMD require frequent injections of anti-vascular endothelial growth factor (anti-VEGF) medications, such as ranibizumab, to slow down the growth of new abnormal blood vessels. To prevent further vision loss, many patients require injections every four to six weeks — a frequency that can be quite time-consuming, and that may pose a challenge for patients with mobility restrictions or significant vision loss.

Vancouver Coastal Health Research Institute researcher Dr. Eduardo Navajas is developing a revolutionary method to transform the treatment of wet AMD. In a pioneering clinical trial, Navajas and his research team are exploring gene therapy as an alternative to frequent injections. 

Instead of repeated injections of ranibizumab, study participants receive a single shot containing copies of the gene responsible for producing ranibizumab. This gene becomes part of the pigmented layer of participants’ retinas, where it starts producing ranibizumab within their retinal tissue, effectively turning retinal cells into miniature drug-producing factories.

Dr. Eduardo Navajas is a clinical researcher at the Vancouver Coastal Health (VCH) Eye Care Centre, and a clinical associate professor and director of resident research in the department of ophthalmology and visual sciences at the University of British Columbia.
Photo courtesy of UBC Faculty of Medicine

"With the patient's own retinas producing the drug, this therapy has the potential to significantly reduce the need for eye injections," explains Navajas. 

“In preliminary studies, some wet AMD patients have not required an injection for up to five years while maintaining their vision.”

Approximately 6,000 anti-VEGF injections are administered each month during visits to ophthalmologists' offices across British Columbia. If Navajas's innovative gene therapy trial succeeds, the therapy he and his team are testing could potentially be integrated into clinical practice in support of greater patient comfort and quality of life while simultaneously enabling health care resources to be redirected to other urgent care needs. 

Nurturing the next generation of physicians and eye care specialists

On top of leading this ground breaking research, Navajas also serves as a clinical mentor, training the next generation of physicians and eye care specialists. For him, teaching is a mutually beneficial experience that enriches his own learning journey. It introduces fresh ideas, acquaints him with the latest research and reignites his passion for his own projects, he states.

"My ultimate goal is to nurture a generation of eye care physicians who approach their work with humility, empathy and an unwavering commitment to lifelong learning."

Working at VCH’s Eye Care Centre, Navajas is part of an innovation incubator that brings together educators, clinicians, research scientists and learners. This cooperative environment empowers collaborations and knowledge-sharing among clinicians and researchers, resulting in cross-pollinations between real-world insights and research investigations for the benefit of individuals throughout the province.

Navajas is currently enrolling participants in his study. Qualifying individuals are required to be between the ages of 50 and 89, and have previously been treated for wet AMD. For more information, please contact the Retina Division at VCH’s Eye Care Centre at 604-875-5475 or retina@eyecarecentre.org.

 

Researchers

Eduardo Navajas

Related Articles

Behind the lab doors: Eye Care Centre

Novel AI model explains retinal sex difference

Ask an expert: How harmful is screen time to my eyes?

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Related Research Centres/Programs

Other Research Focus Areas

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Celebrating the life and distinguished career of Dr. Marcel Dvorak

May 14, 2025
Type
Stories

More equitable representation needed in Parkinson’s research

May 9, 2025 parkinsons, patient engagement, women
Type
Stories

Gamified stroke recovery improves arm function

May 8, 2025 stroke, rehabilitation
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy